Moderna and Pfizer are again seeking Emergency Use Authorization from the FDA on “vaccines” for young children who are not at risk for COVID in the first place. Trial data are already deemed worthless, meaning that the children are being used as guinea pigs. Thus extends the crimes against humanity. ⁃ TN Editor
- Pfizer and Moderna are both seeking emergency use authorization for their bivalent COVID boosters for children. Moderna is seeking authorization for children ages 6 through 17, while Pfizer’s shot is for children aged 5 through 11
- The U.S. Centers for Disease Control and Prevention expects the bivalent boosters will be available for children aged 5 to 11 by mid-October 2022
- In the U.S., both bivalent boosters will contain mRNA against the original Wuhan strain and Omicron variants BA.4 and BA.5. (In the U.K., Moderna’s booster targets the Wuhan strain and BA.1, an earlier Omicron strain no longer in circulation)
- The effectiveness of Pfizer’s booster is based on antibody levels in eight mice, which cannot tell you anything about the level of protection you might receive. Moderna’s booster is also based on antibody levels in mice, although the exact number is unknown
- When it comes to safety, there’s not even mouse data. The safety is assumed based on the original shots, even though the safety data on those is shocking beyond belief. As of September 16, 2022, the U.S. Vaccine Adverse Events Reporting System (VAERS) had logged 55,733 reports of injuries and deaths in children under the age of 18
Even as more damning data are coming to light, Pfizer and Moderna are both seeking emergency use authorization (EUA) for their bivalent COVID boosters for children. Moderna is seeking authorization for children ages 6 through 17, while Pfizer’s shot is for children aged 5 through 11.
According to Reuters, “the U.S. Centers for Disease Control and Prevention … expects COVID-19 vaccine boosters targeting circulating variants of the virus to be available for children aged 5-11 years by mid-October.”
Moderna’s new bivalent COVID booster, mRNA-1273.222, sold under the brand name “Spikevax bivalent Original/Omicron,” was authorized for adults over the age of 18 at the end of August 2022.
In the U.S., the adult dose contains 25 micrograms of mRNA against the original Wuhan strain and 25 mcg of mRNA targeting Omicron variants BA.4 and BA.5. In the U.K., Moderna’s bivalent booster (mRNA-1273.214) contains mRNA against the original Wuhan strain and BA.1, an earlier Omicron strain that is no longer in circulation.
Pfizer’s bivalent booster also contain mRNA against the Wuhan strain, BA.4 and BA.5. The two bivalent boosters are only be available to those who have already received the primary two-dose series and/or a monovalent booster at least two months ago.
It’s probably safe to assume the same rule will apply to children. As of late September 2022, 38% of American children aged 5 to 11 had received one initial dose and 31% have received two doses. In the 12- to 17-year-old age group, 67% have had one dose and 57% two doses. Those with two doses are likely the only ones who will be eligible for the bivalent booster, if authorized.
